[Approaches used for assessment of the burden of advanced schistosomiasis japonica: a comparative study].

Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi

National Institute of Parasitic Diseases, Chinese Center for Diseases Control and Prevention, WHO Collaborating Center for Tropical Diseases, Key Laboratory of Parasite and Vector Biology, National Health Commission, Shanghai 200025, China.

Published: June 2019

AI Article Synopsis

  • The study aims to compare different methods for assessing disability-adjusted life years (DALYs) in patients with advanced schistosomiasis japonica to provide better scientific evidence for its burden.
  • In 2017, patients in Hunan Province were evaluated using three different methods: the common global burden of disease (GBD) estimation, a modified GBD method, and a quality of life assessment.
  • Results showed that the YLDs (years lived with disability) estimates from the modified GBD method and the quality of life method were significantly higher than those from the common GBD method, indicating the latter may underrepresent the condition's burden.

Article Abstract

Objective: To compare the approaches used for the assessment of disability adjust life years (DALYs) for advanced schistosomiasis japonica, so as to provide scientific evidence for accurate assessment of the burden of advanced schistosomiasis japonica.

Methods: The patients with advanced schistosomiasis japonica receiving treatment and assistance programs in Hunan Province in 2017 were enrolled, and the years lived with disability (YLD) for the patients with advanced schistosomiasis japonica was calculated using the common global burden of disease (GBD) estimation method, the modified GBD method with addition of common syndromes of advanced schistosomiasis japonica, and the quality of life assessment method.

Results: The YLDs of patients with advanced schistosomiasis japonica, the mean YLDs per capita, and the percentages of YLD were 673.94, 728.77 person-years and 1 761.99 person-years; 0.181, 0.196 person-years and 0.474 person-years; and 10.61, 11.48 person-years per 100 thousand persons and 27.75 person-years per 100 thousand persons with the common GBD method, modified GBD method and the quality of life method, respectively. The YLDs of the patients with advanced schistosomiasis japonica in Hunan Province estimated with the modified GBD method and the quality of life method were 8.14% and 2.61 times higher than that with the common GBD method. Of the major symptoms included in the calculation, the 5 symptoms with the greatest contribution to the burden of advanced schistosomiasis japonica included ascites, moderate anemia, severe anemia, diarrhea and hematochezia.

Conclusions: The quality of life method may more comprehensively assess the YLDs in patients with advanced schistosomiasis japonica than the common and modified GBD methods.

Download full-text PDF

Source
http://dx.doi.org/10.16250/j.32.1374.2019079DOI Listing

Publication Analysis

Top Keywords

advanced schistosomiasis
40
schistosomiasis japonica
36
patients advanced
20
gbd method
20
modified gbd
16
quality life
16
burden advanced
12
ylds patients
12
life method
12
advanced
10

Similar Publications

Introduction: Schistosomiasis (Bilharzia), a neglected tropical disease caused by parasites, afflicts over 240 million people globally, disproportionately impacting Sub-Saharan Africa. Current diagnostic tests, despite their utility, suffer from limitations like low sensitivity. Polymerase chain reaction (PCR) and quantitative real-time PCR (qPCR) remain the most common and sensitive nucleic acid amplification tests.

View Article and Find Full Text PDF

Hepato-intestinal schistosomiasis is characterized by severe pathological changes at advanced chronic stages, including granulomatous lesions and liver fibrosis. The objective of our research was to assess the dynamic expression of profibrotic molecules, the transforming growth factor beta 1 (TGF-β1), and proinflammatory cytokines immunomodulation induced by interleukin 17 (IL-17) neutralization in murine Schistosomiasis mansoni. The study included 56 specific pathogen-free male C57BL/6 mice, divided into 3 main groups: GI uninfected normal controls, GII S.

View Article and Find Full Text PDF

For over three decades, praziquantel (PZQ) has been the mainstay chemotherapy for prevention and treatment of schistosomiasis. The excessive use of PZQ, coupled with the lack of advanced drug candidates in the current anti-schistosomiasis drug development pipeline, emphasizes the genuine need for new drugs. In the current work, we investigated the antischistosomal potential of a new series of compounds derived from the privileged benzimidazole scaffold, which exhibited low micromolar IC potency in the range of 1.

View Article and Find Full Text PDF

The occurrence of hepatitis E virus (HEV) in patients with Schistosomiasis mansoni (SM) is still poorly understood in Brazil. The objective of this study was to estimate the seroprevalence of anti-HEV IgG in patients with SM and its association with the periportal fibrosis (PPF), assessed by serum markers and ultrasound criteria. This cross-sectional study was carried out in an endemic area in Pernambuco, Brazil, with schistosomal patients who underwent coproscopic survey.

View Article and Find Full Text PDF

In recent decades, technological advancements and scientific progress have significantly improved disease control strategies. However, the exclusive focus on these aspects often overlooks the crucial role of social and cultural factors. Local narratives, reflecting community traditions and beliefs, offer valuable insights that can influence the success of public health interventions.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!